These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 19929209)

  • 21. The solubility-permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation.
    Miller JM; Beig A; Krieg BJ; Carr RA; Borchardt TB; Amidon GE; Amidon GL; Dahan A
    Mol Pharm; 2011 Oct; 8(5):1848-56. PubMed ID: 21800883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery.
    Varma MV; Gardner I; Steyn SJ; Nkansah P; Rotter CJ; Whitney-Pickett C; Zhang H; Di L; Cram M; Fenner KS; El-Kattan AF
    Mol Pharm; 2012 May; 9(5):1199-212. PubMed ID: 22489626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is the full potential of the biopharmaceutics classification system reached?
    Bergström CA; Andersson SB; Fagerberg JH; Ragnarsson G; Lindahl A
    Eur J Pharm Sci; 2014 Jun; 57():224-31. PubMed ID: 24075971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In-situ intestinal rat perfusions for human Fabs prediction and BCS permeability class determination: Investigation of the single-pass vs. the Doluisio experimental approaches.
    Lozoya-Agullo I; Zur M; Wolk O; Beig A; González-Álvarez I; González-Álvarez M; Merino-Sanjuán M; Bermejo M; Dahan A
    Int J Pharm; 2015 Mar; 480(1-2):1-7. PubMed ID: 25595387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system.
    Lindenberg M; Kopp S; Dressman JB
    Eur J Pharm Biopharm; 2004 Sep; 58(2):265-78. PubMed ID: 15296954
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Provisional classification and in silico study of biopharmaceutical system based on caco-2 cell permeability and dose number.
    Pham-The H; Garrigues T; Bermejo M; González-Álvarez I; Monteagudo MC; Cabrera-Pérez MÁ
    Mol Pharm; 2013 Jun; 10(6):2445-61. PubMed ID: 23675957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of risk factors in human bioequivalence study that incur bioinequivalence of oral drug products.
    Yamashita S; Tachiki H
    Mol Pharm; 2009; 6(1):48-59. PubMed ID: 19049413
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Theoretical investigation of passive intestinal membrane permeability using Monte Carlo method to generate drug-like molecule population.
    Sugano K
    Int J Pharm; 2009 May; 373(1-2):55-61. PubMed ID: 19429288
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In situ and in vivo efficacy of peroral absorption enhancers in rats and correlation to in vitro mechanistic studies.
    Sharma P; Varma MV; Chawla HP; Panchagnula R
    Farmaco; 2005; 60(11-12):874-83. PubMed ID: 16243320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan.
    Takagi T; Ramachandran C; Bermejo M; Yamashita S; Yu LX; Amidon GL
    Mol Pharm; 2006; 3(6):631-43. PubMed ID: 17140251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lamivudine permeability study: a comparison between PAMPA, ex vivo and in situ Single-Pass Intestinal Perfusion (SPIP) in rat jejunum.
    Reis JM; Dezani AB; Pereira TM; Avdeef A; Serra CH
    Eur J Pharm Sci; 2013 Mar; 48(4-5):781-9. PubMed ID: 23298578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport.
    Varma MV; Sateesh K; Panchagnula R
    Mol Pharm; 2005; 2(1):12-21. PubMed ID: 15804173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of human pharmacokinetics--gastrointestinal absorption.
    Fagerholm U
    J Pharm Pharmacol; 2007 Jul; 59(7):905-16. PubMed ID: 17637184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biopharmaceutical classification based on solubility and dissolution: a reappraisal of criteria for hypothesis models in the light of the experimental observations.
    Charkoftaki G; Dokoumetzidis A; Valsami G; Macheras P
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):168-72. PubMed ID: 20030634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intestinal permeability of forskolin by in situ single pass perfusion in rats.
    Liu ZJ; Jiang DB; Tian LL; Yin JJ; Huang JM; Weng WY
    Planta Med; 2012 May; 78(7):698-702. PubMed ID: 22411728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of data mining approach to identify drug subclasses based on solubility and permeability.
    Gatarić B; Parojčić J
    Biopharm Drug Dispos; 2019 Feb; 40(2):51-61. PubMed ID: 30635908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-permeability criterion for BCS classification: segmental/pH dependent permeability considerations.
    Dahan A; Miller JM; Hilfinger JM; Yamashita S; Yu LX; Lennernäs H; Amidon GL
    Mol Pharm; 2010 Oct; 7(5):1827-34. PubMed ID: 20701326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effect of Glycyrrhiza inflata and Daphne genkwa on permeabilities of rhodamine 123, a P-glycoprotein substrate across rat jejunum membranes in vitro].
    Huang BB; Li GF; Ren F; Tang ZK; Ma HF; Sun YB; Chen LJ; Yang L
    Zhongguo Zhong Yao Za Zhi; 2008 Nov; 33(21):2521-6. PubMed ID: 19149264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of jejunal absorption and apical efflux of ropivacaine, lidocaine and bupivacaine in the rat using in situ and in vitro absorption models.
    Berggren S; Hoogstraate J; Fagerholm U; Lennernäs H
    Eur J Pharm Sci; 2004 Mar; 21(4):553-60. PubMed ID: 14998587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Toward an increased understanding of the barriers to colonic drug absorption in humans: implications for early controlled release candidate assessment.
    Tannergren C; Bergendal A; Lennernäs H; Abrahamsson B
    Mol Pharm; 2009; 6(1):60-73. PubMed ID: 19183105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.